drugset / Trial / NCT00910455

Study of SRX246 Capsules in Healthy Adult Volunteers

NCT00910455 ↗

Phase 1 Completed 49 enrolled Azevan Pharmaceuticals
RandomizedSingle-groupQuadruple-blind

Summary

This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SRX246 Small molecule — Oral

Indications

No indication recorded.